Maxion Therapeutics
Drug Discovery
- Membership category
- Corporate
Suite 4, The Works Unity Campus, London Road, Pampisford, Cambridge, CB22 3FT, United Kingdom
Maxion Therapeutics at a glance
Maxion Therapeutics is a biotech company based in Cambridge, UK, pioneering drug discovery in diseases driven by ion channel and GPCR proteins.
About Maxion Therapeutics
Maxion has developed an innovative KnotBody® technology that combines the power of millions of years of knottin (naturally occurring miniproteins) evolution in modulating ion channels and GPCRs with state-of-the-art antibody engineering techniques. On their own, knottins are excellent modulators of ion channels but have poor drug-like properties. However, once they are fused onto the surface of antibodies, the resulting “KnotBodies” offer a powerful combination of the functional activity of knottins and the desirable drug properties of antibodies. This revolutionary technology addresses targets that have been off-limits to both small molecules and traditional antibody approaches and results in first-in-class and best-in-class drug candidates.
Founded in 2020 and based in Cambridge (UK), Maxion Therapeutics is driven by an experienced team with an excellent track record. CEO and co-founder Dr John McCafferty (previously co-founder of Cambridge Antibody Technology and IONTAS) and CSO and co-founder Dr Aneesh Karatt-Vellatt (co-founder of IONTAS) co-invented KnotBody technology.
